These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 28780352)
1. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis. Wen H; Ma H; Li P; Zheng J; Yu Y; Lv G Biochem Biophys Res Commun; 2017 Sep; 491(4):1047-1054. PubMed ID: 28780352 [TBL] [Abstract][Full Text] [Related]
2. Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression. Yang L; Zhu JY; Zhang JG; Bao BJ; Guan CQ; Yang XJ; Liu YH; Huang YJ; Ni RZ; Ji LL Tumour Biol; 2016 Mar; 37(3):4115-26. PubMed ID: 26490982 [TBL] [Abstract][Full Text] [Related]
3. High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis. Zhang K; Chen H; Wu G; Chen K; Yang H Med Oncol; 2014 Nov; 31(11):247. PubMed ID: 25260803 [TBL] [Abstract][Full Text] [Related]
4. Upregulation of Far Upstream Element-Binding Protein 1 (FUBP1) Promotes Tumor Proliferation and Tumorigenesis of Clear Cell Renal Cell Carcinoma. Duan J; Bao X; Ma X; Zhang Y; Ni D; Wang H; Zhang F; Du Q; Fan Y; Chen J; Wu S; Li X; Gao Y; Zhang X PLoS One; 2017; 12(1):e0169852. PubMed ID: 28076379 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence. Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752 [TBL] [Abstract][Full Text] [Related]
6. Upregulation of far upstream element-binding protein 1 (FUBP1) promotes tumor proliferation and unfavorable prognosis in tongue squamous cell carcinoma. Chen Y; Liu J; Geng N; Feng C Int J Biol Markers; 2020 Jun; 35(2):56-65. PubMed ID: 32339054 [TBL] [Abstract][Full Text] [Related]
7. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis. Chen K; Mo J; Zhou M; Wang G; Wu G; Chen H; Zhang K; Yang H Med Oncol; 2014 Apr; 31(4):886. PubMed ID: 24535608 [TBL] [Abstract][Full Text] [Related]
8. High expression of Sam68 in sacral chordomas is associated with worse clinical outcomes. Wen H; Li P; Ma H; Zheng J; Yu Y; Lv G Onco Targets Ther; 2017; 10():4691-4700. PubMed ID: 29026317 [TBL] [Abstract][Full Text] [Related]
9. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma. Jiang P; Huang M; Qi W; Wang F; Yang T; Gao T; Luo C; Deng J; Yang Z; Zhou T; Zou Y; Gao G; Yang X J Exp Clin Cancer Res; 2019 Sep; 38(1):400. PubMed ID: 31511046 [TBL] [Abstract][Full Text] [Related]
10. Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma. Zhou M; Chen K; Yang H; Wang G; Lu J; Ji Y; Wu C; Chen C J Neurooncol; 2014 Jan; 116(1):77-82. PubMed ID: 24135846 [TBL] [Abstract][Full Text] [Related]
11. ADAM10 Is a Potential Novel Prognostic Biomarker for Sacral Chordoma. Ding Y; Bui MM; Wang Q; Sun X; Zhang M; Niu X; Tian W Ann Clin Lab Sci; 2019 May; 49(3):309-316. PubMed ID: 31308029 [TBL] [Abstract][Full Text] [Related]
12. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis. Luo P; Wang X; Zhou J; Li L; Jing Z Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233 [TBL] [Abstract][Full Text] [Related]
13. Low expression of PHLPP1 in sacral chordoma and its association with poor prognosis. Chen H; Zhang K; Wu G; Song D; Chen K; Yang H Int J Clin Exp Pathol; 2015; 8(11):14741-8. PubMed ID: 26823799 [TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA KRT8P41/miR-193a-3p/FUBP1 axis modulates the proliferation and invasion of chordoma cells. Wen H; Fu Y; Zhu Y; Tao S; Shang X; Li Z; You T; Zhang W J Bone Oncol; 2021 Dec; 31():100392. PubMed ID: 34712553 [TBL] [Abstract][Full Text] [Related]
15. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300 [TBL] [Abstract][Full Text] [Related]
16. High expression of survivin in sacral chordoma. Chen C; Yang HL; Chen KW; Wang GL; Lu J; Yuan Q; Gu YP; Luo ZP Med Oncol; 2013 Jun; 30(2):529. PubMed ID: 23504337 [TBL] [Abstract][Full Text] [Related]
17. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization. Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of CD40 in sacral chordomas and its correlation with low tumor recurrence. Li X; Wang S; Chen Y; Liu G; Yang X Onkologie; 2013; 36(10):567-71. PubMed ID: 24107910 [TBL] [Abstract][Full Text] [Related]
19. Far upstream element -binding protein 1 (FUBP1) participates in the malignant process and glycolysis of colon cancer cells by combining with c-Myc. Wang S; Wang Y; Li S; Nian S; Xu W; Liang F Bioengineered; 2022 May; 13(5):12115-12126. PubMed ID: 35546072 [TBL] [Abstract][Full Text] [Related]
20. The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC. Wang X; Xing L; Yang R; Chen H; Wang M; Jiang R; Zhang L; Chen J Mol Cancer; 2021 Jun; 20(1):91. PubMed ID: 34116677 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]